Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients

Conditions: Melanoma Stage III; Melanoma Stage IV Interventions: Drug: L19IL2; Drug: L19TNF; Drug: L19IL2/L19TNF; Drug: KEYTRUDA ® Sponsors: Philogen S.p.A.; Merck Sharp& Dohme LLC Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials